No Data
Beigene's commercialized products for multiple indications are included in the new version of the national medical insurance drug list.
Beigene (06160) announced that its self-developed anti-PD-1 antibody drug, Baizean (Tiragolumab injection), and BTK inhibitor, Baiyueze (Zebutini capsule), have added three new indications and one indication has been included in the National Medical Insurance Catalog; Luye Pharma's co-introduced product, Baituowei (Goserelin injection microspheres), has added one indication included in the National Medical Insurance Catalog; Amgen's authorized introduced product, Kyprolis (Carfilzomib for injection), has successfully been renewed. The National Medical Insurance Catalog will be officially implemented starting January 1, 2025. This time the company's products Baizean and Baiyueze.
Three Luye Pharma Products Included in National Reimbursement Drug List
Luye Pharma Gains Ground With New Drug Inclusions
Luye Pharma (02186.HK): If the new drugs (including new indications) developed by Ruo Xinlin and others are included in the national medical insurance pharmaceutical directory for 2024.
Glory 11 Yue 28th luye pharma (02186.HK) announced that a variety of innovative products (including new indications) of the group have been successfully included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Pharmaceutical Catalog (2024)" ("2024 National Medical Insurance Drug Catalog"). This includes the first inclusion of Rosi Lin (Torodevindolafaxine hydrochloride sustained-release tablets); Beitawi (injection Gosheryl microspheres) newly included for breast cancer indications; and Lepusol (docetaxel liposomes for injection) included in the routine catalog. The new version of the National Medical Insurance Drug Catalog will be officially implemented starting January 1, 2025. The company believes
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Hong Kong stocks are moving differently | Most pharmaceutical stocks are rising as the results of the medical insurance negotiations are about to be revealed. Institutions indicate that the sector still has further room for recovery.
Most pharmaceutical stocks are rising, as of the deadline, Keji Pharmaceutical-B (02171) rose by 12.38%, to 7.71 Hong Kong dollars; innocare (09969) rose by 5.36%, to 6.49 Hong Kong dollars; Kainuo Ya-B (02162) rose by 4.3%, to 41.25 Hong Kong dollars.
No Data
No Data
